U.S. Markets closed

OncoGenex Completes Borealis-1 Enrollment

Zacks Equity Research

OncoGenex Pharmaceuticals, Inc. (OGXI) recently announced that it has finished enrolling patients in its phase II study, Borealis-1, which is being conducted to evaluate the survival benefit, safety and tolerability of OGX-427 plus Eli Lilly & Company’s (LLY) Gemzar and Platinol for the treatment of patients with advanced bladder cancer.

The randomized, placebo-controlled phase II study has enrolled roughly 180 patients who will be randomized to receive Gemzar, Platinol, and OGX-427 at two dose-levels (600 mg or 1000 mg) or Gemzar, Platinol and placebo.

While overall survival is the primary endpoint of the study, benefit/risk of the two dosages will be also evaluated using clinical benefit, safety and tolerability outcomes for each dose.

Data from the Borealis-1 study is expected in the second half of 2014.

Another study that is being conducted on OGX-427 for metastatic bladder cancer is Borealis-2. The Borealis-2 study is being conducted in patients suffering from advanced or metastatic bladder cancer whose disease has progressed following initial platinum-based chemotherapy treatment.

OncoGenex’ OGX-427 is in seven phase II studies, namely, Borealis-1, Borealis-2, Pacific, Spruce, OGX-427-PR01, Rainier and Cedar.

The Pacific study is evaluating the benefit of OGX-427 plus Zytiga in patients with castrate-resistant prostate cancer (:CRPC). Patient enrollment is currently in progress. The Spruce study is being conducted for the treatment of previously untreated advanced non-squamous non-small cell lung cancer patients.

Rainieris designed to evaluate the survival benefit of adding OGX-427 to Celgene Corp.’s (CELG) Abraxane plus Gemzar in previously untreated metastatic pancreatic cancer patients.

The Cedar study is evaluating OGX-427 as a first-line therapy in patients suffering from advanced squamous cell lung cancer.

OncoGenex carries a Zacks Rank #3 (Hold). Currently, Jazz Pharmaceuticals (JAZZ) looks moreattractive with a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on OGXI

Read the Full Research Report on LLY

Read the Full Research Report on CELG

Read the Full Research Report on JAZZ

Zacks Investment Research

More From Zacks.com